|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
DPP-4 inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BH01
|
|
gptkbp:bioavailability
|
87%
|
|
gptkbp:CASNumber
|
gptkb:486460-32-6
|
|
gptkbp:chemicalClass
|
triazolopiperazine
|
|
gptkbp:combinationProduct
|
Janumet
|
|
gptkbp:combines
|
gptkb:metformin
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:decreasedIn
|
glucagon secretion
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
antidiabetic agent
|
|
gptkbp:eliminationHalfLife
|
12.4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C16H15F6N5O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sitagliptin
|
|
gptkbp:improves
|
insulin secretion
incretin levels
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Januvia
|
|
gptkbp:mechanismOfAction
|
inhibits dipeptidyl peptidase-4
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:notRecommendedFor
|
gptkb:diabetic_ketoacidosis
children
type 1 diabetes
|
|
gptkbp:patentExpired
|
2022 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adults with type 2 diabetes
|
|
gptkbp:proteinBinding
|
38%
|
|
gptkbp:riskFactor
|
gptkb:bullous_pemphigoid
joint pain
allergic reactions
hypoglycemia (when used with sulfonylureas)
|
|
gptkbp:routeOfAdministration
|
oral tablet
|
|
gptkbp:sideEffect
|
headache
pancreatitis
upper respiratory tract infection
nasopharyngitis
|
|
gptkbp:structureContains
|
fluorine atoms
triazole ring
|
|
gptkbp:synonym
|
MK-0431
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|